Reuters logo
BRIEF-Bristol-Myers announces results from extended follow-up data evaluating opdivo
June 16, 2017 / 11:25 AM / 5 months ago

BRIEF-Bristol-Myers announces results from extended follow-up data evaluating opdivo

June 16 (Reuters) - Bristol-Myers Squibb Co:

* Extended follow-up data evaluating opdivo (nivolumab) shows durable response in adult patients with relapsed or progressed classical hodgkin lymphoma

* Bristol-Myers Squibb- ‍results show overall response rates of 65%/greater with median follow-up of at least 16 months

* Bristol-Myers says as per extended follow-up data evaluating opdivo​, ‍across cohorts, median overall survival not reached, 40% of patients remained on treatment Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below